{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:31:59Z","timestamp":1792279919457,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":190,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 exposed individuals mount an antibody response within around 2-weeks and spike antigen-binding responses correlate well with functional virus neutralization. A minority makes little detectable antibody, generally those with either very mild\/asymptomatic disease or those with severe\/lethal infection. However, in general, antibody titre correlates with viral load and duration of exposure. There is evidence for cross-reactivity with the other human coronaviruses, though the functional impact of this is as yet unclear. Therapeutic use of neutralizing monoclonal antibodies offers potential for clinical use. While there is evidence for neutralizing antibody as a correlate of protection, some cases indicate the potential for full recovery in the absence of antibody. Studies of T-cell immunity following acute infection show CD4 and CD8 responses to epitopes across diverse viral antigens, possible cross-reactivity with epitopes from the common cold human coronaviruses and large-scale activation. However, in severe cases, there is evidence for T-cell lymphopaenia as well as expression of exhaustion markers. Analysis of serum biomarkers of disease severity implicates a hyperinflammatory contribution to pathogenesis, though this has not been mechanistically delineated beyond a likely role of raised IL-6, considered a therapeutic target. Despite rapid progress, there remain pressing unknowns. It seems likely that immune memory to SARS-CoV-2 may be relatively short lived, but this will need longitudinal investigation. Also, this is a disease of highly variable presentation and time course, with some progressing to protracted, chronic symptoms, which are not understood. The contribution of immunopathological mechanisms to tissue damage, whether in the lung, kidney, heart or blood vessels, is unclear. The immunology underlying the differential susceptibility between the very young and the very old is unresolved, a question with ramifications for vaccine roll-out. The greatest challenge relates to rapid generation, testing and manufacture of vaccines that are immunogenic, protective (at least from symptomatic disease) and safe\u2014a challenge that looks achievable.<\/jats:p>","DOI":"10.1093\/oxfimm\/iqaa003","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T13:54:23Z","timestamp":1594302863000},"source":"Crossref","is-referenced-by-count":12,"title":["Adaptive immunity to SARS-CoV-2"],"prefix":"10.1093","volume":"1","author":[{"given":"Daniel M","family":"Altmann","sequence":"first","affiliation":[{"name":"Imperial College, Hammersmith Hospital Department of Immunology and Inflammation, Faculty of Medicine, , London W12 0NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2023011714421421100_iqaa003-B1","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1227","article-title":"Serology assays to manage COVID-19","author":"Krammer","year":"2020","journal-title":"Science"},{"key":"2023011714421421100_iqaa003-B2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.367.6479.727","article-title":"Labs scramble to produce new coronavirus diagnostics","volume":"367","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"2023011714421421100_iqaa003-B3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"2023011714421421100_iqaa003-B4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"2023011714421421100_iqaa003-B5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"2023011714421421100_iqaa003-B6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2023011714421421100_iqaa003-B7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"2023011714421421100_iqaa003-B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.tim.2020.02.001","article-title":"Unveiling the origin and transmission of 2019-nCoV","volume":"28","author":"Xu","year":"2020","journal-title":"Trend Microbiol"},{"key":"2023011714421421100_iqaa003-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2020.09.030","article-title":"A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1\/S2 cleavage site of the spike protein","author":"Zhou","year":"2020","journal-title":"Curr Biol"},{"key":"2023011714421421100_iqaa003-B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"2023011714421421100_iqaa003-B11","author":"Wang","year":"2020"},{"key":"2023011714421421100_iqaa003-B12","author":"Wu","year":"2020"},{"key":"2023011714421421100_iqaa003-B13","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"2023011714421421100_iqaa003-B14","author":"Ng","year":"2020"},{"key":"2023011714421421100_iqaa003-B15","author":"National COVID Testing Scientific Advisory Panel","year":"2020"},{"key":"2023011714421421100_iqaa003-B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3201\/eid1103.040906","article-title":"Longitudinally profiling neutralizing antibody responses to SARS coronavirus with pseudotypes","volume":"11","author":"Temperton","year":"2005","journal-title":"Emerg Inf Dis"},{"key":"2023011714421421100_iqaa003-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.20499","article-title":"Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals","volume":"78","author":"Zhang","year":"2006","journal-title":"J Med Virol"},{"key":"2023011714421421100_iqaa003-B18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1743-422X-7-299","article-title":"Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients","volume":"7","author":"Cao","year":"2010","journal-title":"Virol J"},{"key":"2023011714421421100_iqaa003-B19","author":"Huang","year":"2020"},{"key":"2023011714421421100_iqaa003-B20","author":"Fafi-Kremer","year":"2020"},{"key":"2023011714421421100_iqaa003-B21","author":"Selva","year":"2020"},{"key":"2023011714421421100_iqaa003-B22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imm.12861","article-title":"Prospects from systems serology research","volume":"153","author":"Arnold","year":"2018","journal-title":"Immunology"},{"key":"2023011714421421100_iqaa003-B23","doi-asserted-by":"crossref","first-page":"107725","DOI":"10.1016\/j.celrep.2020.107725","article-title":"Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections","author":"Lv","year":"2020","journal-title":"Cell Rep"},{"key":"2023011714421421100_iqaa003-B24","author":"Ju","year":"2020"},{"key":"2023011714421421100_iqaa003-B25","author":"Shi","year":"2020"},{"key":"2023011714421421100_iqaa003-B26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"2023011714421421100_iqaa003-B27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-med-110118-045506","article-title":"Broadly neutralizing antibodies for HIV prevention","volume":"71","author":"Karuna","year":"2020","journal-title":"Annu Rev Med"},{"key":"2023011714421421100_iqaa003-B28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"2023011714421421100_iqaa003-B29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/cid\/ciy577","article-title":"Bezlotoxumab","volume":"68","author":"Johnson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023011714421421100_iqaa003-B30","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"2023011714421421100_iqaa003-B31","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(20)30985-5","article-title":"What policy makers need to know about COVID-19 protective immunity","volume":"395","author":"Altmann","year":"2020","journal-title":"Lancet"},{"key":"2023011714421421100_iqaa003-B32","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.4049\/jimmunol.181.8.5490","article-title":"T cell responses to whole SARS coronavirus in humans","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"2023011714421421100_iqaa003-B33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat Med"},{"key":"2023011714421421100_iqaa003-B34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"2023011714421421100_iqaa003-B35","author":"Grifoni","year":"2020"},{"key":"2023011714421421100_iqaa003-B36","author":"Thieme","year":"2020"},{"key":"2023011714421421100_iqaa003-B37","author":"Le Bert","year":"2020"},{"key":"2023011714421421100_iqaa003-B38","author":"Matthew","year":"2020"},{"key":"2023011714421421100_iqaa003-B39","author":"Tully","year":"2017"},{"issue":"8","key":"2023011714421421100_iqaa003-B40","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus [published correction appears in PLoS One","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"2023011714421421100_iqaa003-B41","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"key":"2023011714421421100_iqaa003-B42","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","author":"Yu","year":"2020","journal-title":"Science"},{"key":"2023011714421421100_iqaa003-B43","author":"Coomes"},{"key":"2023011714421421100_iqaa003-B44","author":"Yang","year":"2020"},{"key":"2023011714421421100_iqaa003-B45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/path.2274","article-title":"The immunology of sepsis","volume":"214","author":"Sriskandan","year":"2008","journal-title":"J Pathol"},{"key":"2023011714421421100_iqaa003-B46","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"2023011714421421100_iqaa003-B47","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31129-6","article-title":"Kawasaki-like disease: emerging complication during the COVID-19 pandemic","author":"Viner","year":"2020","journal-title":"Lancet"},{"key":"2023011714421421100_iqaa003-B48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00431-017-2937-5","article-title":"Dissecting Kawasaki disease: a state-of-the-art review","volume":"176","author":"Dietz","year":"2017","journal-title":"Eur J Pediatr"}],"container-title":["Oxford Open Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ooim\/advance-article-pdf\/doi\/10.1093\/oxfimm\/iqaa003\/33478471\/iqaa003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ooim\/article-pdf\/1\/1\/iqaa003\/48744303\/iqaa003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ooim\/article-pdf\/1\/1\/iqaa003\/48744303\/iqaa003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T22:17:56Z","timestamp":1673993876000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ooim\/article\/doi\/10.1093\/oxfimm\/iqaa003\/5869360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/oxfimm\/iqaa003","relation":{},"ISSN":["2633-6960"],"issn-type":[{"value":"2633-6960","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020]]},"published":{"date-parts":[[2020]]},"article-number":"iqaa003"}}